文献速递甲状腺疾病

亚临床甲状腺功能亢进对经皮冠状动脉介入治疗患者心血管预后的影响

The Impact of Subclinical Hyperthyroidism on Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

研究连续纳入8283例接受经皮冠状动脉介入治疗的冠心病患者,按甲状腺功能分为甲状腺功能正常组(n=7942)和亚临床甲状腺功能亢进组(n=341),经1:4倾向评分匹配后纳入1603例(亚临床甲亢组332例,甲状腺功能正常组1271例)。Kaplan-Meier分析显示两组主要不良心血管事件无显著差异(11.4% vs 8.8%,log-rank P=.124),Cox回归显示亚临床甲亢不是主要不良心血管事件的独立危险因素(HR 1.33,95%CI 0.92-1.92,P=.127)。

要点

  • 倾向评分匹配后亚临床甲亢组与甲状腺功能正常组主要不良心血管事件发生率无显著差异(11.4% vs 8.8%,log-rank P=.124)。
  • 亚临床甲亢不是经皮冠状动脉介入治疗后主要不良心血管事件的独立危险因素(HR 1.33,95%CI 0.92-1.92,P=.127)。
  • 作者建议未来需更多研究评估促甲状腺激素<0.1 mIU/L的亚临床甲亢对经皮冠状动脉介入治疗患者的长期预测价值。

核心结论

  • 在经皮冠状动脉介入治疗的冠心病患者中,亚临床甲亢与不良心血管事件无独立关联。
  • 作者建议未来需更多研究评估促甲状腺激素<0.1 mIU/L的亚临床甲亢对经皮冠状动脉介入治疗患者的长期预测价值。

研究设计与样本

  • 连续纳入8283例接受经皮冠状动脉介入治疗的冠心病患者,按甲状腺功能分为甲状腺功能正常组(n=7942)和亚临床甲亢组(n=341)。
  • 经1:4倾向评分匹配后纳入1603例,其中亚临床甲亢组332例,甲状腺功能正常组1271例。
  • 主要终点为主要不良心血管事件,即心源性死亡、非致死性心肌梗死和靶血管血运重建的复合终点。

主要发现

  • 倾向评分匹配人群中,主要不良心血管事件发生率亚临床甲亢组11.4% vs 甲状腺功能正常组8.8%,log-rank P=.124,无显著差异。
  • 心源性死亡发生率亚临床甲亢组1.2% vs 甲状腺功能正常组0.9%,log-rank P=.540,无显著差异。
  • 非致死性心肌梗死发生率亚临床甲亢组5.7% vs 甲状腺功能正常组4%,log-rank P=.177,无显著差异。
  • 靶血管血运重建发生率亚临床甲亢组6% vs 甲状腺功能正常组4.7%,log-rank P=.303,无显著差异。
  • Cox回归显示亚临床甲亢不是主要不良心血管事件的独立危险因素(HR 1.33,95%CI 0.92-1.92,P=.127)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者建议未来需更多研究评估促甲状腺激素<0.1 mIU/L的亚临床甲亢对经皮冠状动脉介入治疗患者的长期预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Limited studies have focused on the impact of subclinical hyperthyroidism (SHyper) on poor prognosis in patients with known coronary artery disease (CAD). OBJECTIVE: We implemented the present study to explore the association between SHyper and adverse cardiovascular events in CAD patients who underwent drug-eluting stent implantation. METHODS: We consecutively recruited 8283 CAD patients undergoing percutaneous coronary intervention (PCI). All subjects were divided into 2 groups according to their thyroid function: group 1 (euthyroidism group, n = 7942) and group 2 (SHyper group, n = 341). After 1:4 propensity score (PS) matching, 1603 patients (332 SHyper group and 1271 euthyroidism group) were selected. The primary endpoint was major adverse cardiovascular events (MACEs), a composite of cardiac mortality, nonfatal myocardial infarction (MI), and target vessel revascularization (TVR). RESULTS: Kaplan-Meier (K-M) survival analyses suggested that there was no significant difference in the primary endpoint and secondary endpoints (MACE: 11.4% vs 8.8%, log-rank P = .124; cardiac death: 1.2% vs 0.9%, log-rank P = .540; nonfatal MI: 5.7% vs 4%, log-rank P = .177; and TVR: 6% vs 4.7%, log-rank P = .303) in the PS-matched population. Cox regression analysis indicated that SHyper was not an independent risk factor for MACEs (HR 1.33, 95% CI 0.92-1.92, P = .127). CONCLUSION: SHyper is not independently associated with adverse cardiovascular events in CAD patients undergoing PCI. More studies should be implemented in the future to assess the long-term predictive value of SHyper with thyrotropin levels <0.1 mIU/L for CAD patients undergoing PCI.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yang J, Zheng Y, Li C, et al. The Impact of Subclinical Hyperthyroidism on Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention. J Clin Endocrinol Metab. 2022. PMID: 34850030. doi:10.1210/clinem/dgab855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。